Orthocell has announced record quarterly revenue of $2.73 million for the June quarter – our fifth consecutive quarter of record revenue growth.
First US Surgical Use of Remplir™
Orthocell recorded first use of Remplir™ in the US overnight, which is an important step in establishing surgical experience and knowledge of the product.
Breakthrough Study Confirms Remplir™ Superiority Over Standard US Nerve Repair Technique
Orthocell has today announced interim results from a new study demonstrating that Remplir™ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques.
Stockhead | Interview with Dr Ian Valerio
During his visit to Australia last week for Orthocell’s annual nerve repair and reconstruction symposium, US reconstructive surgeon Dr Ian Valerio made the time to speak with Stockhead’s Tylah Tully about the significant global opportunity for Remplir, following recent FDA approval.
The West Australian | Biotech’s easy cell to crack American market
An article in The West Australian has highlighted Orthocell’s rapid progress in securing 12 US distributors across 21 states for our flagship nerve repair product Remplir™.
Orthocell Receives Regulatory Approval for Remplir™ in Hong Kong
Orthocell has received regulatory approval from the Hong Kong Department of Health’s Medical Device Division to commence sales of Remplir™ in the Hong Kong nerve repair market.
Orthocell US Remplir™ Sales Rollout Gains Pace with 12 Distributors Now Appointed Covering 21 States
Orthocell has appointed 12 US distributors for its nerve repair product Remplir™, well ahead of the expected target of 10 distributors by 30 June.
Orthocell Secures Health Canada Approval for Remplir™ in US$75 million Canadian Market
Orthocell has secured a Medical Device Licence from Health Canada for Remplir™, opening access to the US$75 million Canadian nerve repair market.
Orthocell Receives Regulatory Approval to Commence Sales of Remplir™ in US$84 million Thai market
Orthocell has been granted a licence by the Food and Drug Administration of Thailand to commence sales of Remplir™ into the significant and growing US$84 million Thai nerve repair market.
Orthocell Appoints its First Four US Remplir™ Distributors
Orthocell has appointed four US distributors for its flagship nerve repair product Remplir™, enabling the commencement of commercial distribution into the US.